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Abstract 
Objective: To modify a published group intervention for adjustment to multiple sclerosis (MS) to suit an 
individual format, and to assess the feasibility of a randomised controlled trial (RCT) to compare individual and 
group intervention for people with multiple sclerosis and low mood. 
Design: Feasibility randomised controlled trial. 
Setting: Participants were recruited through healthcare professionals at a hospital-based multiple sclerosis 
service and the MS Society. 
Subjects: People with multiple sclerosis. 
Interventions: Adjustment to multiple sclerosis in individual or group delivery format.  
Main measures: Participants completed mood and quality of life assessments at baseline and at 
four-month follow-up. Measures of feasibility included: recruitment rate, acceptability of randomisation 
and the intervention (content and format), and whether the intervention could be adapted for individual 
delivery. Participants were screened for inclusion using the General Health Questionnaire -12 and 
Hospital Anxiety and Depression Scale, and were randomly allocated to receive either individual or 
group intervention, with the same content. 
Results: Twenty-one participants were recruited (mean age 48.5 years, SD 10.5) and were randomly 
allocated to individual (n=11) or group (n=10) intervention. Of those offered individual treatment, nine 
(82%) completed all six sessions. Of those allocated to group intervention, two (20%) attended all six 
sessions and three (30%) attended five sessions. There were no statistically significant differences 
between the groups on the outcome measures of mood and quality of life.  
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Introduction 
Cognitive behavioural therapy is an established 
psychological treatment for mood disorders, with an 
extensive evidence base, and has been found to 
facilitate the adjustment process for people diag-
nosed with multiple sclerosis.
1
 A review of the 
effectiveness of cognitive behavioural therapy for 
people with multiple sclerosis
2
 identified seven ran-
domised controlled trials (RCTs) comparing cogni-
tive behavioural therapy with a control condition. 
These included evaluations of cognitive behavioural 
therapy using individual format (n=3), group format 
(n=3), and computerised format (n=1). Meta-
analysis revealed a significant positive effect of 
cognitive behavioural therapy on depression for 
people with multiple sclerosis. An indirect compari-
son of individual and group intervention showed no 
significant differences in treatment outcomes. A 
further recent evaluation of combined face-to-face 
and telephone cognitive behavioural therapy sup-
ported these findings,
3
 especially for those with 
moderate levels of distress. 
Another review of psychological interventions 
for people with multiple sclerosis focused on the 
format of intervention, i.e. group interventions, 
rather than interventions based on a specific psy-
chological model.
4
 This review of 14 studies con-
cluded that group psychological interventions were 
less effective than individual cognitive behavioural 
therapy or medication for depression in the short 
term but had comparable long-term outcomes.
4
 
However, a meta-analysis was not conducted. 
Some studies have suggested that it is the group 
context, in which there is interaction with other 
people that is of primary importance,
5
 but none 
have provided a direct comparison of individual  
and group interventions with similar content. 
Forman and Lincoln’s6 pilot RCT evaluating a six-
session adjustment group intervention based on 
cognitive behavioural therapy principles for people 
with multiple sclerosis and low mood, showed a 
significant positive effect on depressive symptoms. 
Lincoln et al.
7
 further supported the results of this 
pilot study and showed that this adjustment group 
improved mood and reduced the impact of multiple 
sclerosis on daily life. It was also shown to be cost-
effective.
8
 
Therefore, there is no clear consensus of the rel-
ative merits and limitations of both formats of this 
intervention. The aim of our study was to assess the 
feasibility of an RCT to compare the format of an 
adjustment group based on cognitive behavioural 
therapy principles,
6,7
 and to compare the effect of the 
format of delivery of the intervention (individual or 
group) on mood and quality of life. 
Method 
The study was a single centre, feasibility ran-
domised controlled trial comparing a group psy-
chological adjustment intervention based on 
cognitive behavioural therapy principles with the 
same intervention delivered on an individual basis. 
Ethical approval was granted by Nottingham 
Research Ethics Committee 1. 
Participants were recruited through the National 
Health Service (NHS) and MS Society. Clinicians 
working in NHS Multiple Sclerosis Clinics in 
Nottingham invited people with multiple sclerosis 
to take part. Patients were given information about 
the study, including a participant information sheet 
with a reply slip to return their contact details to the 
researchers if they were interested in taking part. 
Potential participants were contacted by the 
researchers and were sent a screening pack, con-
taining two mood measures, the General Health 
Questionnaire-12 (GHQ-12)
9
 and the Hospital 
Anxiety and Depression Scale (HADS),
10
 to com-
plete and return by post. Study posters were dis-
played on the MS Society website and in their local 
branch newsletters. Those who were recruited 
through the MS Society were also sent a screening 
pack to return by post. 
Participants were included if they had a diagnosis 
of multiple sclerosis and scored three or more out of 
12 on the GHQ-12 or eight or more out of 21 on the 
HADS Anxiety or Depression subscales. 
Participants who were eligible for inclusion were 
contacted by telephone and an appointment was 
made to further discuss the study and to complete a 
consent form. Baseline assessments were adminis-
tered in a single one-hour session at the university or 
at participants’ homes by a clinical psychologist or a 
trained research psychologist. Participants were 
excluded if they did not speak English and if they 
were unable to attend group sessions (if they were to 
be allocated to group treatment). 
Those who met the criteria and who gave 
informed consent were included. Personal details, 
demographic characteristics, type and duration of 
multiple sclerosis were recorded. Participants then 
completed the following baseline measures: (i) 
Guy’s Neurological Disability Scale (GNDS),11 a 
12-item scale that assesses impairments due to 
multiple sclerosis in the following areas: cognition, 
mood, vision, communication, swallowing, upper 
limb, lower limb function, bladder, bowel, sexual, 
fatigue, and ‘other’ problems. The range of possi-
ble scores is between 0 and 60, with higher scores 
indicating greater levels of disability. (ii) Beck 
Depression Inventory-II (BDI-II),
12
 a 21-item 
measure of severity of depressive symptoms, which 
has been used in previous trials of psychological 
intervention for people with multiple sclerosis. 
Higher scores indicate greater depression. (iii) 
Multiple Sclerosis Impact Scale-29 (MSIS),
13
 a 
disease-specific quality of life scale with good 
psychometric properties. It comprises 20 items on  
physical impact of multiple sclerosis and nine 
items on psychological impact of multiple sclero-
sis. Higher scores indicate a greater impact of mul-
tiple sclerosis on quality life. (iv) Multiple 
Sclerosis Self-efficacy Scale (MSSE),
14
 a14-item 
scale to assess the extent to which participants felt 
in control of their condition. Higher scores indicate 
greater self-efficacy. 
Participants were asked whether they would 
prefer individual or group treatment, but were 
informed that the allocation would be random. 
This was to ascertain preference and to determine 
whether dropouts were related to not receiving the 
preferred treatment. Participants were randomly 
allocated to either individual or group treatment 
(1:1 ratio). Randomisation was conducted using a 
web-based random number generator by an inde-
pendent researcher who was not involved in the 
assessment or intervention. The group treatment 
programme was offered to 3–8 participants who 
were all able to attend the specified location on the 
same dates. Individual treatment was arranged at 
times to suit each participant and conducted in par-
ticipants’ homes or at the university. 
Treatment sessions were delivered by a clinical 
psychologist or a trained research psychologist. 
Both received supervision from experienced 
researchers with a background in clinical psychol-
ogy and working with people with multiple 
sclerosis. Both treatments were conducted in 
accordance with the written, structured group 
manual developed by Forman and Lincoln.
6
 
Adaptations were made to the group manual 
handouts and worksheets, as required, to suit the 
individual format. Both treatments were designed 
to be delivered in six sessions, although the 
content of the individual treatment could be 
delivered flexibly across sessions (i.e., therapists 
could complete content in one or more sessions, 
depending on the needs of the participants). 
Group sessions were video recorded to monitor 
the fidelity of the intervention. Videos allowed us 
to determine who was saying what, which audio 
recordings alone would not have allowed us to do 
easily. This was not a problem for individual 
sessions (where there were only two speakers), so 
audio recordings were used instead. 
At four months after random allocation, partici-
pants were sent a booklet of outcome question-
naires to complete and return by post using a pre-
paid reply envelope. The measures included GHQ-
12,
9
 HADS,
10
 BDI-II,
12
 MSIS
13
 and MSSE.
14
 These 
assessments were used because they tapped into the 
outcomes of interest for this study (mood and 
quality of life). In addition to this, we included a 
measure of self-efficacy (i.e., perceived capability 
or control), because treatment may improve self-
efficacy and it is believed to influence both mood 
and quality of life in people with multiple 
sclerosis.
15
 Outcome data were entered onto a data-
base by a researcher blind to group allocation. 
Analyses were conducted using SPSS version 21. 
Results 
The flow of participants through the study is 
shown in Figure 1. 
We had an 80% (n=27) response rate for return 
of screening questionnaires, and 62% (n=21) of 
potential participants met the inclusion criteria. 
The demographic and baseline characteristics of 
participants are shown in Table 1. One participant 
(shown in the table as an unknown type of multiple 
sclerosis) was later found to have a diagnosis of 
neuromyelitis optica, but was retained in the study. 
Prior to randomisation, participants were asked 
to state their treatment format preference to deter-
mine whether participants had a strong preference 
which if not met could have influenced their deci-
sion to continue with the trial, but reminded that 
allocation would be random. Seven participants did 
not report a treatment preference, seven preferred 
to be allocated to group treatment and seven to 
individual treatment. Of the four participants who 
did not attend for treatment, three were not allo-
cated to their preferred treatment. 
Of the 11 allocated to individual treatment, we 
were unable to contact one participant who there-
fore received no treatment. Of the 10 allocated to 
group treatment, seven participants were treated in 
one group and three in another. The reasons for 
non-attendance at any group sessions were 
bereavement, a relapse, and not being offered their 
preferred treatment format. 
Individual sessions lasted approximately one 
hour, and group sessions lasted approximately two 
hours. 
Outcome questionnaires were returned by 16 
(76%) of the participants, eight (73%) allocated to 
individual treatment and eight (80%) allocated to 
group treatment. The distributions of scores on the 
outcome assessments are shown in Table 2. 
The groups were comparable in demographic 
characteristics at baseline. The data were not nor-
mally distributed, and the sample size was small, 
so non-parametric statistics were used. 
The two groups were compared on the outcome 
measures using Mann Whitney U tests. There were 
no statistically significant differences between the 
groups (P=0.07 to P=0.57), but on all outcome 
measures the scores were better for individual than 
group treatment. The effect sizes ranged from 0.29 
(BDI-II) to 0.86 (GHQ-12). These suggest that 
there is a considerable benefit of individual 
therapy over group therapy. 
Based on the effect size for the MSIS 
Psychological subscale (0.40), we conducted a 
sample size calculation for a definitive trial. With 
80% power and an alpha of 0.05, for a two-tailed 
test, a sample size of 96 per group will be needed. 
Discussion 
The study design was feasible and acceptable to 
people with multiple sclerosis. The manualised 
individual treatment was feasible, had better 
attendance rates and appeared to have better out-
comes compared to the group format, which is 
consistent with previous meta-analyses.
4
 
Recruitment was slower than expected but 
achievable. Based on our previous experience, we 
had anticipated recruiting approximately six par-
ticipants per month, but in reality this was closer to 
three per month. As 21% of those invited did not 
return the screening questionnaires, a definitive 
study would benefit from sending reminder letters 
or where possible, a single phone call to remind 
potential participants. Also, providing the option for 
participants to consent and complete the screening 
questionnaires at their routine clinic visits may 
improve recruitment and response rates. 
 
 
Figure 1. Trial flowchart. 
One participant did not attend treatment because 
of not being allocated to their preferred treatment, 
so for most participants (95%) randomisation was  
acceptable. Outcomes were completed by 76%, 
and suggest that postal or telephone reminders or 
face-to-face follow-up assessments would be 
 
  
 
Table 1. Baseline demographic and clinical characteristics. 
   
Characteristics Individual treatment 
n= 11 
Group treatment 
n= 10 
n % n % 
Gender     
Men 3 27 3 30 
Women 8 73 7 70 
Marital status     
Single 2 18 5 50 
Married/partnered 8 73 5 50 
Widowed/divorced/separated 1 9 0 0 
Living arrangements     
Alone 2 18 4 40 
With family/partner 9 82 6 60 
Ethnicity     
White British 11 100 7 70 
Other 0 0 3 30 
Type of multiple sclerosis     
Relapsing remitting 9 82 5 50 
Progressive 1 9 3 30 
Benign 1 9 0 0 
Not known 0 0 2 20 
Currently receiving MS disease modifying medication 8 73 6 60 
Currently receiving antidepressant medication 3 27 4 40 
Other medical conditions 3 27 6 60 
Recruitment source     
MS Society newsletter 6 55 8 80 
Hospital 5 45 2 20 
Treatment preference     
Individual 3 27 4 40 
Group 4 36 3 30 
Either 4 36 3 30 
Allocated to treatment preference     
Yes 3 27 3 30 
No 4 36 4 40 
Indifferent 4 36 3 30 
 Mean SD Mean SD 
Age (years) 48.9 10.4 48 11.2 
Time since diagnosis 9.3 6.8 8.9 6.4 
Guys Neurological Disability Scale 20.6 7.8 22.3 8.2 
n=sample size; SD=standard deviation.     
 
needed in a definitive trial to improve completion 
rates. 
The acceptability of the content of the interven-
tion was established by Forman and Lincoln,
6
 but  
we wanted to know whether this was acceptable 
for delivery in one-to-one sessions. The individual 
treatment was well received by participants and 
adherence was very good, with 88% of sessions 
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attended. Adherence in the group intervention was 
lower, with 55% of sessions attended. 
Attendance at group sessions has been found to 
be a problem previously and the proportion attend-
ing was consistent with that found in previous 
research.
16
 One hypothesis is that the success of the 
groups is dependent on group cohesion, which is 
often linked to shared identities, ideologies, and 
interests. While all participants had low mood and 
multiple sclerosis, this in itself may not have been 
sufficient to foster cohesion. For the Holmes et al.
16
 
study, non-attendance was more common among 
men than women. They were in the minority in 
each group and may not have been able to connect 
to the others. Another hypothesis is that people 
may feel more obliged to attend individual rather 
than group sessions, because the focus of therapy is 
solely on them and not on others in the former. Yet 
another hypothesis is that people may have felt 
they were getting more out of the individual ses-
sions than the group sessions, which may reflect 
the differences in the outcomes between the 
different delivery formats (considered below). 
Furthermore, individual sessions allowed for more 
focus on certain topics considered relevant for each 
individual. For instance, if the participant was very 
anxious, the focus was more on the worry sessions 
than others. If a topic was not as relevant, then this 
was only covered briefly. Also, individual sessions 
could be rearranged in the event of participant 
illness or other commitments, whereas it was 
difficult to reschedule group sessions at short 
notice. The reason for one participant not attending 
group sessions was difficulty with travel and this 
did not occur in those allocated to individual 
therapy, as treatment sessions could be conducted 
in participants’ homes. 
In terms of the completeness of outcome data, 
five (24%) were lost to follow-up and there was 
complete data on 16 participants (76%) at the 4-
month outcome. The loss to follow-up was not 
related to attendance at treatment sessions. Indeed, 
only one had not attended any sessions, and two 
had attended all sessions. In a definitive study, with 
longer follow-up periods, it may be beneficial to 
have regular phone or email contact with all 
participants to ensure that they remain interested  
in the study. More flexible means of collecting 
these outcomes should also be considered, such 
as online surveys or mobile phone apps, or even 
by collecting the data over the phone. These 
strategies may improve quality and amount of 
outcome data. However, direct contact with 
participants raises the risk of the outcome 
assessor becoming unblinded. 
Scores on mood measures were better for indi-
vidual treatment than group treatment at the 4-month 
outcome assessment, but these differences were not 
statistically significant. However, they are clinically 
important differences which suggest there may be 
advantages of individual treatment. The lack of sta-
tistically significant results was influenced by the 
small sample size. The effect sizes varied between 
0.29 and 0.86 but five of the seven effect sizes calcu-
lated were greater than 0.5, which indicated medium 
effect and suggests that with a larger sample differ-
ences in outcome may be detected. Based on this, we 
calculated the parameter estimates for a fully 
powered study, and determined that a sample size of 
96 per group would be needed for a definitive trial. 
Imbalance between groups in terms of type of multi-
ple sclerosis, and the small sample size meant that the 
effect of type of multiple sclerosis on outcomes could 
not be determined. 
No serious adverse events were reported during 
treatment, but two participants who received indi-
vidual treatment continued to report suicidal 
thoughts but with no intent to carry them out, which 
related to their response on the baseline Beck 
Depression Inventory score on the ‘suicidal 
thoughts’ item. Both cases were assessed by a clini-
cal psychologist and neither was deemed to be at 
risk of suicide, but for one participant, it was agreed 
that the research team would pass on this informa-
tion to their General Practitioner. A recent system-
atic review found higher suicide rate in people with 
multiple sclerosis compared to the general popula-
tion.
17
 Suicide risk, therefore, needs to be monitored 
carefully in future studies. 
The study design was feasible and acceptable to 
people with multiple sclerosis. The manualised 
individual treatment was feasible and seemed to be 
beneficial, but needs to be tested in an adequately 
powered RCT. Furthermore, the cost-effectiveness 
of individual and group treatments needs to be 
ascertained. 
We advocate that clinicians consider a mixed 
individual and group intervention, with individual 
treatment available for those who do not wish to 
attend groups. In such a mixed format, it may be 
possible to harness the strengths of both individual 
(e.g., individualised treatment, person-centred care, 
therapeutic alliance, better adherence, space to 
discuss some aspects in private) and group (e.g., 
therapeutic effects of the group, possibilities for 
socialisation and identity formation, sharing of 
information) delivery formats. This mixed format 
mimics some clinical interventions, but the clinical 
and cost-effectiveness of this specific intervention 
for people with multiple sclerosis is yet to be 
evaluated. 
Clinical Messages 
 More patients with multiple sclerosis 
offered psychologically-based adjustment 
therapy attended individual rather than 
group sessions. 
 The study found a trend towards better 
outcomes after individual treatment; it 
was not statistically significant. 
 A randomised controlled study including 
about 200 patients would be needed to 
establish the actual relative effectiveness. 
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